Coronado announces IND submission for TSO for chronic plaque psoriasis

December 9, 2013

Coronado Biosciences announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to begin a Phase 2 clinical study of Trichuris suis ova for the treatment of moderate to severe chronic plaque psoriasis. Coronado is also pursuing the trial based upon preliminary results from open-label investigator-sponsored trials at two U.S. centers that are currently evaluating multiple doses of TSO in patients with psoriasis. Coronado's proposed Phase 2 trial is a U.S. multi-center, dose-ranging study that will use the Psoriasis Area and Severity Index score from week 0 to week 12 to assess efficacy. Coronado intends to begin enrolling patients in the trial during the first quarter of 2014 if the IND application is approved.